Lifeboat Foundation

Researchers at DTU Health Tech have developed a new material that can facilitate a near-perfect merger between machines and the human body for diagnostics and treatment.

A DTU research team consisting of Malgorzata Gosia Pierchala, Firoz Babu Kadumundi, and Mehdi Mehrali from #TeamBioEngine headed by Alireza Dolatshahi-Pirouz, have developed a new material—CareGum—that among other things has potential for monitoring motor impairment associated with neurological disorders such as Parkinson’s.

The White House recently announced its vision for an Advanced Research Projects Agency for Health, or ARPA-H. RAND researchers explain what it might take to ens… See More.

DARPA also maintains an extremely high tolerance for failure. The modest budgets of the NIH, combined with an enormous pool of applicants, force these institutions to bet on low-risk research that guarantees incremental progress. ARPA-H could take a different approach than NIH by accepting a much higher tolerance for failure, so that researchers are not discouraged from dreaming big.

The scientific methods behind the products of ARPA-H might gain public trust if the agency made a point of being transparent and accessible. Consider how the rapid development of the COVID-19 vaccine was met with incredulity and suspicion, slowing progress toward herd immunity. An investment in ARPA-H could accelerate the time it takes to get innovative ideas from “bench to bedside,” but it could benefit from informing the public about incremental advancements in a way that is easy to understand.

Continue reading “Biden’s Proposed New Health Agency Would Emphasize Innovation. Here’s How It Might Work” »

HSE doesn’t expect health services to return to normal for “a number of weeks” as it continues to deal with the fallout of the ransomware attack against critical IT infrastructure.

Scientists may have found a promising new treatment for Covid-19 after an experimental oral antiviral drug demonstrated the ability to prevent the coronavirus from replicating, the National Institutes of Health said Thursday, citing a new study.

The drug, called TEMPOL, can reduce Covid-19 infections by impairing an enzyme the virus needs to make copies of itself once it’s inside human cells, which could potentially limit the severity of the disease, researchers at the NIH said. The drug was tested in an experiment of cell cultures with live viruses.

“We urgently need additional effective, accessible treatments for COVID-19,” Dr. Diana W. Bianchi, director of the NIH’s National Institute of Child Health and Human Development, wrote in a statement. “An oral drug that prevents SARS-CoV-2 from replicating would be an important tool for reducing the severity of the disease.”

Summary: Findings of a new study could help to design better strategies to improve sleep in workers with atypical work schedules.

Source: McGill University.

Getting enough sleep can be a real challenge for shift workers affecting their overall health. But what role does being an early bird or night owl play in getting good rest? Researchers from McGill University find a link between chronotype and amount of sleep shift workers can get with their irregular schedules.

Circa 2017

Learn how Stanford Health Care brings together leading-edge technology, innovative research, and world-renowned experts to meet your unique needs.

CRISPR-based technologies offer enormous potential to benefit human health and safety, from disease eradication to fortified food supplies. As one example, CRISPR-based gene drives, which are engineered to spread specific traits through targeted populations, are being developed to stop the transmission of devastating diseases such as malaria and dengue fever.

But many scientists and ethicists have raised concerns over the unchecked spread of gene drives. Once deployed in the wild, how can scientists prevent gene drives from uncontrollably spreading across populations like wildfire?

Continue reading “Synthetic SPECIES developed for use as a confinable gene drive” »

A first-in-human, Phase 1 trial assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine designed to provide long-lasting protection against multiple flu virus strains has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. Healthy participants 18 to 50 years old will receive either a licensed seasonal influenza vaccine or the experimental vaccine, FluMos-v1. Scientists from NIH’s National Institute of Allergy and Infectious Diseases (NIAID) developed FluMos-v1 to stimulate antibodies against multiple influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds. Alicia T. Widge, M.D., of NIAID’s Vaccine Research Center (VRC), is the principal investigator of the NIAID-sponsored single-site trial.

“The health and economic burdens of influenza are substantial, and the world badly needs improved flu vaccines,” said NIAID Director Anthony S. Fauci, M.D. “I am encouraged by the great promise of the VRC nanoparticle vaccine candidate, which so far has performed very well in pre-clinical testing.”

Standard influenza vaccines must be reformulated and administered annually to match changes in the HA protein in the viral strains predicted to dominate in the upcoming influenza season. If the vaccine is not well matched to dominant circulating virus strains, the antibodies elicited may provide sub-optimal protection. So-called universal influenza vaccines are being developed and tested by many research groups and could one day eliminate the need for annual vaccination by generating long-lasting antibodies to protect against many existing or emergent influenza virus strains, including those not represented in the vaccine.

Today, Sunday, May 30, 2021, at 1 p.m. Pacific Time, join us for a U.S. Transhumanist Party Virtual Enlightenment Salon with Ryan O’Shea, as we discuss the state of the transhumanist movement, life-extension advocacy, biohacking, Ryan’s Future Grind podcast, and more!

Watch on YouTube here:. You will be able to post questions and comments in the live YouTube chat.

Continue reading “U.S. Transhumanist Party Virtual Enlightenment Salon with Ryan O’Shea — May 30, 2021” »